BeOne Medicines, formerly known as BeiGene, is a global biotechnology company focused on developing and commercializing innovative cancer treatments.
The Senior Business Analytics & Insights Manager delivers commercial and performance insights for Spain and Portugal.
The Study Start-up Specialist manages and coordinates clinical trial initiation activities across multiple sites. This role ensures regulatory compliance and efficient trial startup.
The Regional Access Manager optimizes product access by building strategic relationships with regional payers and stakeholders.
A Senior Medical Science Liaison will manage scientific exchange and KOL engagement in oncology. The role offers a competitive salary and involves significant field travel.
Senior Product Manager responsible for developing marketing strategies for Hematology in Spain and Portugal.
BeOne Medicines, formerly known as BeiGene, is a global biotechnology company focused on developing and commercializing innovative cancer treatments. With a mission to make oncology medicines more accessible and affordable worldwide, the company operates across the entire value chain, from research and development to manufacturing and commercialization. BeOne Medicines has a significant global footprint, with teams across North America, Europe, Asia, and other regions, and is recognized as a key player in the oncology space.
In Spain, BeOne Medicines has established a presence to support its clinical development and commercial activities, with roles based in Madrid and Barcelona. The company is actively expanding its operations in Europe, and its Spanish offices contribute to global clinical trials and medical affairs. For international professionals, BeOne Medicines offers an opportunity to work in a fast-paced, science-driven environment with a mission to impact cancer care globally. The company values diversity and collaboration, and its Spanish teams work closely with global counterparts, making it an attractive option for those looking to advance their careers in the biotech industry.
BeOne Medicines, formerly known as BeiGene, was founded in 2010 by a team of scientists and business leaders with a vision to develop cancer treatments that are more affordable and accessible. The company quickly grew, listing on the NASDAQ in 2016 and later on the Hong Kong Stock Exchange, and expanded its global operations. In 2024, the company rebranded to BeOne Medicines to reflect its broader mission and global reach, while continuing to focus on oncology innovation.